<?xml version="1.0" encoding="utf-8"?>
<items><story><date>06:40 03 January 2007 (UTC)</date><text>NEW YORK Jan 3 Durect Corp. (DRRX.O) said on
Wednesday it had started midstage testing in the United States
for Transdur-Bupivacaine, a transdermal pain patch for patients
suffering from post-shingles pain.

</text><link>http://www.reuters.com/article/2007/01/03/durect-trial-idUSWEN168020070103</link><sectors></sectors><title>durect begins phase ii testing of pain patch</title></story></items>